Volixibat potassium
|
|
|
- CAS号:
- 220334-14-5
- 英文名:
- Volixibat potassium
- 英文别名:
- A-6 peptide;P1161 Angstrom6;Volixibat potassium;Angstrom6/A6 Peptide;L-α-Glutamine, N2-acetyl-L-lysyl-L-prolyl-L-seryl-L-seryl-L-prolyl-L-prolyl-L-α-glutamyl-
- 中文名:
- Volixibat potassium
- 中文别名:
- 化合物 T26629;单链尿激酶纤溶酶原激活剂多肽;单链尿激酶纤溶酶原激活剂八肽
- CBNumber:
- CB33160003
- 分子式:
- C39H62N10O15
- 分子量:
- 910.98
- MOL File:
- 220334-14-5.mol
|
|
|
Volixibat potassium化学性质
-
沸点:
-
1469.3±65.0 °C(Predicted)
-
|
-
密度:
-
1.409±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
酸度系数(pKa):
-
4.44±0.10(Predicted)
-
|
Volixibat potassium性质、用途与生产工艺
Angstrom6 (A6 Peptide) 是一种来源于单链尿激酶纤溶酶原激活剂 (scuPA) 的8个氨基酸的肽，可干扰 uPA/uPAR 级联反应并消除下游效应。Angstrom6 与 CD44 结合，抑制肿瘤细胞的迁移、侵袭和转移，调节 CD44 介导的细胞信号。
Angstrom6 is effective at blocking the migration of the OVCAR8, OVCAR3, ES2, IGROV-1, MDA-MB-468, and MDA-MB361 cells with IC
50
s in the range of 10 to 100 nM.
Angstrom6 potentiates the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation.
Angstrom6 (100 mg/kg; s.c. twice daily) reduces the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50%.
|
Animal Model:
|
C57Bl/6 mice (bearing B16-F10 cells)
|
|
Dosage:
|
100 mg/kg
|
|
Administration:
|
S.c.; twice a day for 11 days
|
|
Result:
|
Reduced the number of lung nodules and reduced the number of lung metastases to 50% of control.
|
Volixibat potassium
上下游产品信息
上游原料
下游产品
220334-14-5, Volixibat potassium 相关搜索:
- 目录肽
- 定制多肽
- 单链尿激酶纤溶酶原激活剂多肽
- 化合物 T26629
- 单链尿激酶纤溶酶原激活剂八肽
- 220334-14-5
- P1161 Angstrom6
- L-α-Glutamine, N2-acetyl-L-lysyl-L-prolyl-L-seryl-L-seryl-L-prolyl-L-prolyl-L-α-glutamyl-
- A-6 peptide
- Angstrom6/A6 Peptide
- Volixibat potassium